Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells
- 1 February 2017
- journal article
- Published by Elsevier in Toxicology in Vitro
- Vol. 38, 117-123
Abstract
No abstract availableKeywords
Funding Information
- South African National Research Foundation (85703, 92741)
This publication has 42 references indexed in Scilit:
- Epidermal growth factor receptor‐targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penisBJU International, 2013
- PUMA and BIM Are Required for Oncogene Inactivation–Induced ApoptosisScience Signaling, 2013
- A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: Validation with daunomycin, doxorubicin, and the alpha particle emitter 210PoNuclear Medicine and Biology, 2012
- Advances in Treatment of Lung Cancer With Targeted TherapyArchives of Pathology & Laboratory Medicine, 2012
- Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugsInternational Journal of Radiation Biology, 2011
- The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeuticsApoptosis, 2011
- Changes in Lognormal Shape Parameter Guide Design of Patient-Specific Radiochemotherapy CocktailsJournal of Nuclear Medicine, 2011
- BacMam-Enabled LanthaScreen® Cellular Assays for PI3K/Akt Pathway Compound Profiling in Disease-Relevant Cell BackgroundsSLAS Discovery, 2010
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cellsProceedings of the National Academy of Sciences, 2009
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006